Cediranib
Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma
Fred Hutchinson Cancer CenterSmall moleculePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
7 Active assets in the Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Ifosfamide David Bond, MD | Phase 4 | BBB |
ETOPOSIDE University of Washington | Phase 4 | BBB |
Carboplatin David Bond, MD | Phase 2 | BB |
cc-5013 David Bond, MD | Phase 2 | BB |
Loncastuximab Tesirine City of Hope Medical Center | Phase 2 | CCC |
View all 13 →
Same molecule, other indications
Cediranib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →